Učitavanje...
Combined Erlotinib and PF‐03084014 treatment contributes to synthetic lethality in head and neck squamous cell carcinoma
OBJECTIVES: Head and neck squamous cell carcinoma (HNSCC) is characterized by high mortality and low survival rates. As an epidermal growth factor receptor (EGFR) inhibitor, Erlotinib has been approved for treatment of various tumours. PF‐03084014 is a selective inhibitor of Notch1 signalling. This...
Spremljeno u:
| Izdano u: | Cell Prolif |
|---|---|
| Glavni autori: | , , , , , , , , |
| Format: | Artigo |
| Jezik: | Inglês |
| Izdano: |
John Wiley and Sons Inc.
2017
|
| Teme: | |
| Online pristup: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6528911/ https://ncbi.nlm.nih.gov/pubmed/29232766 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/cpr.12424 |
| Oznake: |
Dodaj oznaku
Bez oznaka, Budi prvi tko označuje ovaj zapis!
|